Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Breast Neoplasms × Injections, Subcutaneous × Clear all

Phase

Phase 3 2 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 1 Breast Neoplasms 1

Interventions

Trastuzumab 250 Cyclophosphamide 212 Paclitaxel 210 Docetaxel 202 Capecitabine 158 Letrozole 136 Carboplatin 132 Doxorubicin 122 Fulvestrant 120 Bevacizumab 102 Tamoxifen 85 Anastrozole 85 Vinorelbine 79 exemestane 75 Epirubicin 75 Gemcitabine 72 Lapatinib 70 pertuzumab 68 Radiotherapy 62 Albumin-Bound Paclitaxel 61 pembrolizumab 58 eribulin 50 palbociclib 49 Cisplatin 47 130-nm albumin-bound paclitaxel 45 Everolimus 41 Neoadjuvant Therapy 37 Taxes 36 Goserelin 36 pyrotinib 33

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04675827 2024-12-04

Decrescendo

Jules Bordet Institute

Phase 2 Terminated

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡